Personalized cancer vaccine plus atezolizumab shows clinical activity in cancer patients

Written by Lucy Chard, Editor

mRNA cancer vaccine nanoliposomes

Nanosystems are being used as a safe and efficient mode of delivery for personalized cancer vaccines. RO7198457 is an mRNA-based therapeutic cancer vaccine that targets tumor-associated antigens, which are expressed in the individual patient’s cancer. The cancer vaccine shows immunostimulatory and antineoplastic potential. In this latest study presented at the 2020 AACR Virtual Annual Meeting II, the RO7198457 cancer vaccine was used in combination with PD-L1 inhibitor atezolizumab (Tecentriq),  in a Phase Ib clinical trial. This particular cancer vaccine is best delivered via a nanoencapsulation method using liposomes as this enables more efficient targeting for personalized medicines. RO7198457 is manufactured...

To view this content, please register now for access

It's completely free